Stock Research: Adaptive Biotechnologies

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Adaptive Biotechnologies

NasdaqGS:ADPT US00650F1093
60
  • Value
    20
  • Growth
    81
  • Safety
    Safety
    14
  • Combined
    11
  • Sentiment
    100
  • 360° View
    360° View
    60
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Adaptive Biotechnologies Corporation is a biotechnology company focused on harnessing the adaptive immune system for disease diagnosis and treatment. It operates in the fields of Minimal Residual Disease (MRD) with its clonoSEQ clinical diagnostic test, and Immune Medicine, discovering and developing immune-based therapies for cancer and autoimmune diseases. In the last fiscal year, the company had 619 employees, a market cap of $1701 million, profits of $107 million, and revenue of $179 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 60 (better than 60% compared with alternatives), overall professional sentiment and financial characteristics for the stock Adaptive Biotechnologies are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Adaptive Biotechnologies. The consolidated Growth Rank has a good rank of 81, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 81% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 100, which means that professional investors are more optimistic about the stock than for 100% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 14, which means that the share price of Adaptive Biotechnologies is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 86% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 20, which means that the company has a financing structure that is riskier than those of 80% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
14 6 55 25
Growth
81 99 71 29
Safety
Safety
20 8 98 87
Sentiment
100 80 57 47
360° View
360° View
60 47 94 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
87 64 67 42
Opinions Change
97 28 50 50
Pro Holdings
n/a 82 39 83
Market Pulse
84 75 49 26
Sentiment
100 80 57 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
14 6 55 25
Growth
81 99 71 29
Safety Safety
20 8 98 87
Combined
11 19 94 56
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
60 60 60 10
Price vs. Earnings (P/E)
24 39 59 17
Price vs. Book (P/B)
16 4 60 55
Dividend Yield
1 1 1 1
Value
14 6 55 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
19 91 88 70
Profit Growth
73 60 61 28
Capital Growth
78 88 58 70
Stock Returns
93 95 21 9
Growth
81 99 71 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
27 30 100 100
Refinancing
39 23 75 49
Liquidity
25 28 26 n/a
Safety Safety
20 8 98 87

Similar Stocks

Discover high‑ranked alternatives to Adaptive Biotechnologies and broaden your portfolio horizons.

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

CF Industries

NYSE:CF
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.